Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q33408024

about

Targeted Radionuclide Therapy of Human Tumors PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow Theranostic applications of antibodies in oncology.PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges Radioisotopes in management of metastatic prostate cancer Tumor immunotargeting using innovative radionuclides Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).Molecular Imaging of Prostate Cancer Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer In vitro method to observe E-selectin-mediated interactions between prostate circulating tumor cells derived from patients and human endothelial cells Targeted alpha anticancer therapies: update and future prospects Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy Development of targeted near-infrared imaging agents for prostate cancer Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.Molecular imaging of urogenital diseases.A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.Immunotherapy in prostate cancer: review of the current evidence.Next revolution in molecular theranostics: personalized medicine for urologic cancers.Emerging agents for the therapy of advanced prostate cancer.Antibody-mediated delivery of therapeutics for cancer therapy.Radioimmunoconjugates for treating cancer: recent advances and current opportunities.Emerging clinical applications of PET based molecular imaging in oncology: the promising future potential for evolving personalized cancer care.Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.Small-molecule PSMA ligands. Current state, SAR and perspectives.Relevance of radiobiological concepts in radionuclide therapy of cancer.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease Drug discovery in advanced prostate cancer: translating biology into therapy.Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.Antibody-targeted nanoparticles for cancer treatment.

P2860

Q26771267-8D37618D-AB43-4C5A-B8BC-4B2CE0A15615 Q26774920-FD66A1F5-5F51-47AE-87DD-B7EA18F57E1A Q27334142-411B3193-8600-4838-B321-14D47FD921AC Q27693293-9609232D-0931-4FB5-A4F7-6FEFC9C3552F Q28067404-AD381A17-74D7-482A-9671-734B1EA274CE Q28068134-A577855B-67A9-4708-83D0-D5D38AD4894D Q28083230-3EDD5C6A-4E8B-47E7-B0C3-AD4498EA119F Q33410060-11E0E32A-5C41-498A-8A78-7124F6ED8891 Q33581903-F8311229-A3CB-42FC-A60C-B42F898B68F0 Q33586706-7BD75851-238F-422D-9ECF-C6FA4B882F50 Q33620520-746DBDC9-4D00-4614-9CB2-1440DAE50581 Q33818963-0BE5C3EA-42F4-45A1-8E60-5BCD82DDE97E Q34300114-89449E28-196E-45A7-8A83-342A0EE570E1 Q34511439-E15F8F6D-1DA6-4C33-8352-CBFD7C285246 Q34655256-D071A3E1-1939-4515-8B35-406A7B129625 Q35282416-BDA32057-258F-4823-9768-D976E8B1C0C1 Q35544056-26D4E5C6-6632-4241-A464-831501D6EDDD Q35754837-62255DB3-CF02-4ED3-A96B-7A32518175AE Q35959942-E03B8761-FFCA-4737-A598-17479F23C490 Q36245624-3735000D-2677-4CEB-AA84-4C4E8524ECF8 Q36491493-2DDFE305-A988-4F44-BB52-F816EEF270ED Q36928870-6DF26AC4-558F-431B-8ADA-ED77821343A8 Q37175085-244D4E7F-41E8-47EB-BFAB-EF09CE4B41F2 Q37550399-4009A436-D42F-41B9-AFEF-4D688D33EA1B Q37644883-74EE1E68-4FB9-4E81-A1EC-14B7CBC0CC95 Q37662701-0BE632C8-2E60-40AB-80E7-380F3AB99ED1 Q38169828-3FD7347E-DF31-4E61-8892-928A022FBE1B Q38283918-3D17DE4B-62EB-4650-BF6D-09E0CCB642C1 Q38559336-D0970A88-8CA2-4546-8804-BC99603BBC55 Q38586459-45BDBBC5-4110-42C2-8F5E-1058D8FE5226 Q38665425-B0C35794-C4A0-4E23-8E08-52A149C7AB88 Q38691472-2D72018B-B4B1-4C5F-878B-3B75686EE4BD Q38692408-CAE08528-8547-4C45-B665-A2C3A19C8E44 Q38699173-A931AFB9-4F1C-4865-9759-C79FFDBE65D1 Q38737674-9F029155-2334-44DC-81EA-BD40B25573F9 Q38751028-EE155334-E24D-4B1C-B0A0-5A66921CF106 Q38831232-41342962-D04C-45C8-B6B3-C66C171F21D8 Q38839110-37B1948B-0B98-47CE-913D-3CFB3EC2DC10 Q38861197-1913765E-DAE6-4F70-AFB1-02B9EF7B264F Q38887307-7CCC3730-FD60-4925-83E0-E868153AF813

P2860

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q33408024

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase II study of Lutetium-177 ...... ion-resistant prostate cancer.

@ast

Phase II study of Lutetium-177 ...... ion-resistant prostate cancer.

@en

type

label

Phase II study of Lutetium-177 ...... ion-resistant prostate cancer.

@ast

Phase II study of Lutetium-177 ...... ion-resistant prostate cancer.

@en

prefLabel

Phase II study of Lutetium-177 ...... ion-resistant prostate cancer.

@ast

Phase II study of Lutetium-177 ...... ion-resistant prostate cancer.

@en

P1433

Q33408024-272C643B-F16F-43A5-94F5-960A097AEDE0

P1476

Q33408024-BECAA32F-7E5F-442E-AB24-E7ABBA892C44

P2093

Q33408024-0E43EA48-A036-40F4-B705-2F8B29DC7AAC

Q33408024-3796A916-0722-424E-96E8-3804A5A67245

Q33408024-3C7A01B3-2B75-4784-900F-3E430CC31B33

Q33408024-4849705F-9787-4BFD-8AFB-A15800667F9D

Q33408024-6504D422-24D4-41FC-B1F0-2F71BD5B8CEB

Q33408024-6F44F393-D298-4261-8ADB-11A8681589F2

Q33408024-8B75109C-1D89-48B7-BBB5-11A6CEE949FC

Q33408024-8BF94465-5401-47A7-B83D-9BFF0CB9B8F3

Q33408024-D13C9DBA-2B1E-4879-BA77-82AA82B61B84

Q33408024-D91C2CEA-59E3-4D5B-A668-E1FF6974BAA5

P2860

Q33408024-0388735E-4919-47DA-A350-5CDA7EFC8607

Q33408024-053EF76E-1F7F-4201-A47C-5AA466F53112

Q33408024-05F4E990-FC61-4E9D-B1FA-C735B6833A91

Q33408024-07907C3A-A730-4D6C-AC0F-CC159ECAD9A8

Q33408024-11284C5F-E691-41F4-ACFD-0CD0352F8224

Q33408024-14D5D25C-ED06-4498-8866-2DDA7AEECF33

Q33408024-167AFBA4-115C-4E7C-84A1-8AF8607A3E32

Q33408024-2096862D-4C17-4B7D-9420-91C6957F1C2E

Q33408024-23798F44-4DBA-4E19-BBE3-154410B90B73

Q33408024-23C42EA7-0E84-4A87-AA2A-CD4809B46B2B

P304

Q33408024-377427C0-3FA4-4C57-8892-CEA1651CB72B

P31

Q33408024-BCD9A421-30C8-4109-99AF-0A17E5A2ED4C

P356

Q33408024-76BB15EF-5E2D-4E41-9F98-81FDED43B8D3

P407

Q33408024-AABFC92F-D439-48A7-9D61-6ACDFBB50259

P433

Q33408024-7B04E30A-8B26-4A47-83E0-2AE30D779D8F

P478

Q33408024-676053CE-8F05-4CB6-8831-6144889F8FB0

P50

Q33408024-E385A5F4-507B-456E-9EE2-B1F43D98B5F5

P577

Q33408024-1FD5A0D7-3CE7-4ACA-9CC2-2B5FB19FE921

P698

Q33408024-0273EE9F-AA43-4F10-BBAE-066577542E11

P921

Q33408024-36DDA718-1BF6-48C8-90F2-464F1BBFD87B

P932

Q33408024-F3DCEEC9-A8B8-427F-BC7E-4B32824AC0CE

P356

1078-0432.CCR-13-0231

P1433

Clinical Cancer Research

P1476

Phase II study of Lutetium-177 ...... ion-resistant prostate cancer.

@en

P2093

David M Nanus

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Matthew I Milowsky

http://www.w3.org/2001/XMLSchema#string

Michael Morris

http://www.w3.org/2001/XMLSchema#string

Naveed H Akhtar

http://www.w3.org/2001/XMLSchema#string

Neeta Pandit Taskar

http://www.w3.org/2001/XMLSchema#string

Neil H Bander

http://www.w3.org/2001/XMLSchema#string

Paul Christos

http://www.w3.org/2001/XMLSchema#string

Scott T Tagawa

http://www.w3.org/2001/XMLSchema#string

Shankar Vallabhajosula

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

A Phase II Study of [90Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy

Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer.

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.

P304

5182-5191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0231

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Joseph R Osborne

P577

2013-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23714732

http://www.w3.org/2001/XMLSchema#string

P921

P932

3778101

http://www.w3.org/2001/XMLSchema#string